secwatch.observer — SEC 8-K summary
======================================

Issuer:     Cabaletta Bio, Inc. (CABA)
CIK:        0001759138
Form:       8-K
Filed at:   2023-03-16T23:59:59+00:00
Accession:  0001193125-23-071942
Event type: earnings
Sentiment:  neutral
Materiality: 0.70
Item codes: 2.02, 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Cabaletta Bio Q4 2022: cash $106.5M, CABA-201 IND expected H1 2023, data H1 2024
--------------------------------------------------------------------------------

- R&D expenses $12.4M (Q4) and $39.3M (FY2022), up from $9.9M and $32.5M YoY.
- Cash and investments $106.5M at Dec 31, 2022; funding expected into Q1 2025.
- CABA-201 IND clearance expected H1 2023; initial clinical data anticipated H1 2024.
- Raised $32.6M net in December 2022 public offering of pre-funded warrants and common stock.
- DSG3-CAART combination sub-study data (1-month) expected H1 2023; MuSK-CAART trial initiated Nov 2022.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1759138/000119312523071942/0001193125-23-071942-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1759138/000119312523071942/d409494d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-23-071942

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer